Navigation Links
New Study Showed Lantus(R) Plus One, Two or Three Shots of Apidra(R) Lowered Patients' Blood Sugar
Date:6/6/2009

- Study Presented at 69th Annual ADA Scientific Sessions Examined Efficacy and Safety of Basal-Prandial Treatment with Lantus(R) and Apidra(R) -

NEW ORLEANS, June 6 /PRNewswire-FirstCall/ -- Sanofi-aventis U.S. presented results of a new study, "Effects of 1, 2, or 3 Prandial Injections of Insulin Glulisine on Glycemic Control in Type 2 Diabetes Patients on Insulin Glargine and Oral Drugs," evaluating patients adding prandial insulin Apidra(R) (insulin glulisine [rDNA origin] injection) administered before 1 meal, 2 meals or 3 meals daily, already taking basal insulin, Lantus(R) (insulin glargine [rDNA origin] injection), with or without oral antidiabetic drugs (OADs).The study was presented as a poster during the 69th Annual Scientific Sessions of the American Diabetes Association (ADA).

The study was a multicenter, randomized, open-label, parallel group study in insulin naive patients. Lantus(R) was started for a 14-week run-in period, after which time patients not at goal (A1C<7%) at week 0 were randomized to a 24-week intensified regimen of Lantus(R) plus Apidra(R) administered as above. Dose was adjusted to achieve an A1C<7%, fasting plasma glucose (FPG) and preprandial blood glucose < 110 mg/dl, and bedtime blood glucose < 130 mg/dl. FPG, Lantus(R) dose, and weight did not differ significantly among the 3 arms. Overall incidence and severity of adverse events (AEs) were comparable among the 3 treatment arms. The most frequently reported AEs included upper respiratory tract infections (5.2%), peripheral edema (4.1%), pain in extremity (3.8%), nasopharyngitis (3.5%), sinusitis (3.2%), and back pain (3.2%). A greater but nonsignificant proportion of patients experienced serious and severe hypoglycemia with Apidra(R) 3 times daily compared with those receiving Apidra(R) once or twice daily. The rates of symptomatic or severe hypoglycemia were not statistically significant between groups.


'/>"/>
SOURCE sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
2. Study Demonstrating Lurasidone Is Effective in Patients With Schizophrenia Published in The Journal of Clinical Psychiatry
3. IMPACT Study Showed Longer Valcyte(R) (valganciclovir hydrochloride tablets) Treatment Demonstrated Better Protection Against Cytomegalovirus (CMV) Disease One Year Post-Transplant
4. Data From Clinical Study of bioTheranostics Molecular Diagnostic Test Presented at American Society of Clinical Oncology Annual Meeting
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Trubion Announces Positive Data From a Phase 1 / 2 Study of TRU-016 for the Treatment of Chronic Lymphocytic Leukemia (CLL)
7. Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients
8. Results and Additional Analyses From Study Show That Cortheras Relaxin for Acute Heart Failure is the Strongest Predictor of Improved Longer-Term Outcomes Following Hospital Discharge When Compared to Other Variables
9. Ironwood and Forest Present Additional Positive Phase 2b Study Results for Linaclotide in Patients With Irritable Bowel Syndrome With Constipation
10. Study Showed Lillys GEMZAR(R) (gemcitabine HCl for injection) Improved Progression-Free Survival in Cervical Cancer Patients
11. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/27/2009)...,, CHICAGO,Nov.27/PRNewswire/--Attheupcoming...ngstartingSunday,RoyalPhilipsElectronics(PHG,AEX:P...nformaticssolutionsdesignedtodirectlyaddressthepri...ingfulimaginginnovationsthatreflectadesireforvalue...illenablePhilipstoprovidecontinuedaccesstoadvanced...
(Date:11/25/2009)...,, WESTON,Fla., Nov.25/PRNewswire-FirstCall...)("theCompany")ispleasedtoannouncethattheyhaveopen...nShanghai,China. ,, ASRhasbeenabletosecurealoca...pmentandproductionofcurrentandfuturehealthandsafet...dglobally.Currentlythecompanyhousesinventoryinthes...
(Date:11/25/2009)...,, PRINCETON,N.J.,Nov.25/PRNewswire-FirstCal...harmaceuticalcompanycommittedtodiscovering,develop...ons,reportedfinancialresultsforthefiscalyearendedS...8.4millionincash,cashequivalentsandshortterminvest..., RG7128 ,, Phase2bTrial ,, InlateNov...
Breaking Medicine Technology:Philips Helps Hospitals Strike Balance Between Innovation and Value 2Philips Helps Hospitals Strike Balance Between Innovation and Value 3Philips Helps Hospitals Strike Balance Between Innovation and Value 4American Scientific Resources Inc. Opens Shanghai Location 2Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate 5501 1NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate 5501 2NCCN Updates NHL Guidelines Following FDA Approval of Pralatrexate 5501 3Fewer Genital Warts Thanks to HPV Vaccine Program 59521 1Fewer Genital Warts Thanks to HPV Vaccine Program 59521 2Halos of Hope ASTRO partner to raise awareness of cancer survivorship 59519 1
(Date:11/26/2009)... bigger thrill when on an emotional rollercoaster,...thDay News) -- Call it the fear factor meets the j... spectators -- especially those who root for the w...it,s a closely contested match and victory was in ...r. , Chew on that this Thanksgiving weekend as ...
(Date:11/26/2009)... Dr. David Kim of the Live Life Aga...y in Dallas , is one of a growing number of physic...etworking sites to connect with individuals who ar...fight morbid obesity. Dr. Kim is utilizing Faceboo... about his practice with the community. , ...
(Date:11/26/2009)... Benton Communications announces a ...h system for retailers struggling to make an econo...ovember 26, 2009 -- Flu fears is the type of chall...mergency room, according to Dr. David Benton, busi...d business growth system – The Rfactor Inte...
(Date:11/25/2009)...INA,Minn.,Nov.25/PRNewswire-USNewswire/--Whenmostp...achiropractorcanalsogivepatientsthehelptheyneed.TM...yourjaw(mandible)contacts/connectswithyourskull(te...withTMJdysfunctionarepainwithchewing,clickingorpop...Jdysfunctionincluding:headaches,fatigue,sleepdistu...
(Date:11/25/2009)...ERYVILLE,Calif.,Nov.25/PRNewswire-FirstCall/-- On...dthatthecompanywillhosttwoinvestoreventsinDecember...0a.m.CT/10:00a.m.ET ,, Principalinvestigators...inrelapsedand/orrefractorymultiplemyeloma,asfeatur...eetingandExpositioninNewOrleans,LA.Theteleconferen...
Breaking Medicine News(10 mins):Health News:Watching the Nail-Biting Big Game Hurts So Good 2Health News:Watching the Nail-Biting Big Game Hurts So Good 3Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 2Health News:Dallas Texas Weight Loss Surgeon Using Social Media To Reach Out to Patients 3Health News:Pharmacist Injects Cure for Ailing Businesses 2Health News:Onyx Pharmaceuticals Announces December 2009 Investor Events 2
...es Association/National Nurses Organizing Committe...tee for resisting enormous pressure to,pass a badl...legislators,community groups, and labor for genuin...gratulated the committee "for its thorough, delibe...
...dical, Inc.,announced today that it has obtained r...L6 Retrievers in the European Union. These new Ret...n the existing Merci,Retrievers(R) already on the ...d L6 Retrievers join Concentric Medical,s L family...
...sty cough is now a lot easier thanks to a new test...been approved by U.S. Food and Drug Administration...est simultaneously detects the most prevalent resp...es Mahony, in conjunction with Luminex Molecular D...
...n in future , , MONDAY, Jan. 28 (HealthDay...e might one day ward off the flu. , Not only would...re convenient, it also appears to be more effectiv...edles, but it,s clearly an introductory study and ...
...kinson and Company) (NYSE: BDX ), a global medica... present at the Merrill Lynch Global,Pharmaceutica...Thursday,February 7, 2008 at 10:20 a.m. (ET)., Th...rough Thursday, February 14, 2008., BD, a leading...
...as increase dramatically for patients whose tumors...hers at Saint Louis University and the M.D. Anders...ecifically evaluate the link between tumor size an...ly underscore the importance of early diagnosis of...
Other Medicine News:Health News:RNs Praise Courageous Vote by Senate Committee on Badly Flawed Healthcare Bill 2Health News:RNs Praise Courageous Vote by Senate Committee on Badly Flawed Healthcare Bill 3Health News:Concentric Medical Announces European Release of Expanded Family of Neurovascular Retrievers for use in Stroke Patients 2Health News:McMaster test detects the most prevalent respiratory viruses 2Health News:Drop of Flu Vaccine Under Tongue Bars Infection 2Health News:Pancreatic cancer: The smaller the tumor, the better your chances, study shows 2Health News:Pancreatic cancer: The smaller the tumor, the better your chances, study shows 3
New Image Cut-to-Fit Convex FlexWear Skin Barrier
New Image Cut-to-Fit Convex Flextend Skin Barrier
CenterPointLock Urostomy Pouch
CenterPointLock Stoma Cap
Medicine Products: